Results from IMBITRA clinical study have been presented at the 53rd SEN Congress 2023
Results from IMBITRA study of Immunobiogram in renal transplant patients in maintenance phase have been presented at the 53rd SEN Congress 2023, which took place in Palma de Mallorca on November 11th – 13th.
IMBITRA study described the sensitivity profile to individual immunosuppressants measured in vitro with Immunobiogram in two groups of patients: patients with a graft rejection and patients with opportunistic infections (BK virus and CMV). 74 patients from 9 Spanish sites were included, 43 with rejection and 31 with opportunistic infections. The clinical event had occurred in the last 2 years in both groups.
The study has shown that Immunobiogram measures the patient’s pharmacodynamic response in vitro to individual immunosuppressive drugs. Patients with rejection tended to show lower sensitivity to the IMS they were taking prior to the event, while patients with opportunistic infections presented a tendency to show higher sensitivity to the prescribed IMS.
